AB-1015 is under clinical development by Arsenal Biosciences and currently in Phase I for Peritoneal Cancer. According to GlobalData, Phase I drugs for Peritoneal Cancer have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AB-1015’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AB-1015 overview
AB-1015 is under development for the treatment of ovarian cancer, fallopian tube cancer and primary peritoneal cancer. The therapeutic candidate comprises T cells which are genetically engineered to knockdown FAS and PTPN2 and to express chimeric antigen receptor (CAR) targeting antigens ALPG/P and MSLN. Knockdown of FAS and PTPN2 results in CAR T cells that are resistant to FAS-mediated apoptosis and enhanced in vivo expansion. The drug candidate is administered through intravenous route.
Arsenal Biosciences overview
Arsenal Biosciences is a cell therapy company that discovers, develops and commercializes immune cell therapies to treat cancer. It utilizes its synthetic biology compositions made up of PrimeR logic gates, CARchitecture acquired gene expression controls, and CellFoundry mediated nonviral manufacturing to develop cell therapy product candidates. Arsenal Biosciences was funded by Kleiner Perkins, Westlake Village Biopartners, Euclidean Capital, Osage University Partners and UCSF foundation investment company. The company works in collaboration with Bristol Myers Squibb Co to evaluate T cell therapies for the treatment of solid tumors. Arsenal Biosciences is headquartered in South San Francisco, California, the US.
For a complete picture of AB-1015’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
Smarter leaders trust GlobalData
Premium Insights Likelihood of Approval and Phase Transition Success Rate Model - AB-1015 in Peritoneal Cancer
Premium Insights
The gold standard of business intelligence.
